Michael Burry
Scion Asset Management
Michael Burry THERAVANCE BIOPHARMA INC stake
total: 173
Scion Asset Management TBPH trades
- Total transactions:
- 4
- New positions:
- 1
- Sold out:
- 1
- Added:
- 1
- Reduced:
- 1
- Held since:
- 2015 Q4
- Held for:
- 3 quarters
- Latest activity:
- 2016 Q3
According to 2025 Q3 report, Michael Burry doesn't hold any THERAVANCE BIOPHARMA INC (TBPH) shares. To date, the estimated cost basis is nearly $17.04 for "buy" trades and estimated average "sell" price is $21.4. Scion Asset Management first purchased TBPH in 2015 Q4, initially acquiring 436,626 shares. Since the initial investment in THERAVANCE BIOPHARMA INC (TBPH), Scion Asset Management has made 3 more transactions.
When did Michael Burry sell THERAVANCE BIOPHARMA INC (TBPH)?
Michael Burry sold off the entire THERAVANCE BIOPHARMA INC (TBPH) position in 2016 Q3.
When did Michael Burry buy THERAVANCE BIOPHARMA INC (TBPH)?
Michael Burry first invested in THERAVANCE BIOPHARMA INC (TBPH) in 2015 Q4 at the reported quarter-end price of $16.39 per share.
What's the cost basis of Scion Asset Management's TBPH stake?
The estimated cost basis for THERAVANCE BIOPHARMA INC (TBPH) stake is around $17.04 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $17.04
- Weighted AVG sell price:
- $21.40
Michael Burry's historical trades in THERAVANCE BIOPHARMA INC
4 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2016 Q3
|
0.00%
|
$22.69
|
-100% (-325,000)
|
|||
|
2016 Q2
|
16.21%
|
$22.69
|
+18.18% (+50,000)
|
|||
|
2016 Q1
|
10.12%
|
$18.80
|
-37.02% (-161,626)
|
|||
|
2015 Q4
|
8.95%
|
$16.39
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.